ABSTRACT OBJECTIVES This study assessed 5 frequently applied arterial 18 fluorodeoxyglucose ( 18 F-FDG) uptake metrics in healthy control subjects, those with risk factors and patients with cardiovascular disease (CVD), to derive uptake thresholds in each subject group. Additionally, we tested the reproducibility of these measures and produced recommended sample sizes for interventional drug studies.
A therosclerosis is a chronic, low-grade inflammatory disease of the arterial wall that causes myocardial infarction and stroke (1) . Despite aggressive primary and secondary prevention strategies, long-term disability and death from cardiovascular disease (CVD) continue to increase (2) . Arterial inflammation is strongly related to the risk of atherosclerotic plaque rupture. Quantification of inflammation may improve patient risk stratification and allow new drug therapies to be tested (1) .
Noninvasive imaging, in particular with 18 F-fluordeoxyglucose ( 18 F-FDG) positron emission tomography (PET), has been used in this way (3, 4) . Arterial wall 18 F-FDG uptake mirrors inflammatory activity in atherosclerosis (5-7); inflammatory cells consume large amounts of glucose in comparison with other plaque cells. This results in 18 F-FDG accumulation. In addition, arterial 18 F-FDG uptake is higher in morphologically unstable plaques and predicts future vascular events (8-13). 18 F-FDG PET can assess the efficacy (or futility) of treatments designed to lower plaque inflammation (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . As shown in Online Table 1 , the number of vascular intervention trials using 18 F-FDG PET as a surrogate marker of inflammation is growing, with one-half being published in the past 2 years. Several of these studies enriched their study populations by excluding subjects with 18 F-FDG uptake below predefined thresholds. However, a consensus regarding the most appropriate thresholds is lacking (28) (29) (30) (31) , primarily because healthy subjects, presumably without pathological arterial inflammation, have not been systematically imaged, and large-scale prospective outcome studies are awaited (32, 33) . Without these data, it is challenging to enroll patients with sufficient arterial inflammation to need therapy and to avoid randomizing those unlikely to respond.
In this study, we assessed 5 frequently applied arterial 18 F-FDG uptake metrics in 3 distinct groups:
healthy control subjects, those with risk factors for CVD, and a group with established CVD. Considering 18 F-FDG uptake in the arterial wall of healthy control subjects as physiological, we determined the 90th percentile for arterial wall inflammatory activity using several commonly reported PET endpoints. Finally, we determined the reproducibility of published measures of 18 F-FDG uptake and derived optimal sample sizes for drug studies based on our results.
METHODS STUDY POPULATION.
We recruited subjects into 3 groups: 1) healthy control subjects; 2) patients at Arterial PET/CT van der Valk et al.
Arterial PET/CT in Atherosclerosis Table 2 ).
ACTIVE SEGMENT APPROACH. We also examined the TBR of the most-diseased segment TBR (Online Table 2 ). In addition, an active segment analysis was performed using several pre-defined cutoffs. Using a Values are mean AE SD, % (n), or median [IQR] . *p value between all groups. †p value between patients at increased CVD risk and patients with known disease. ‡Agatston score.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CAC score ¼ coronary artery calcium score; CRP ¼ C-reactive protein; DBP ¼ diastolic blood pressure; HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; NS ¼ not significant; SBP ¼ systolic blood pressure; TChol ¼ total cholesterol; TG ¼ triglycerides.
Arterial PET/CT in Atherosclerosis cutoff of TBR $1.60 for the carotids, 48% of the healthy control subjects had at least 1 active slice compared with 96% and 100% of the patients at increased risk for or with known CVD, respectively ( Table 2 ). The percentage of active slices was 32 AE 40% in healthy control subjects, 80 AE 31% in patients at risk for CVD, and 90 AE 19% in known CVD patients (p ¼ 0.020). The corresponding TBR active slices values were also distinct between groups (p ¼ 0.044) (Table 2). With cutoffs of $1.80 or $2.00, the number of healthy control subjects with at least 1 active slice in the carotids decreased substantially (Online Table 3 ).
Whereas the % active slices remained significantly different between groups, the TBR active slices did not (Online Table 3 ).
In contrast to the carotids, a much larger proportion of the subjects had active aortic walls. With a cutoff of $2.40, 88% of the healthy control subjects had at least 1 active slice; however, the TBR active slices and % active slices were not distinct between groups ( Table 2) . With the active definition at $2.60 or $2.80, more than one-half of the healthy control subjects still had active segments (Online Table 3 ). For the highest cutoff, TBR active slices was significantly different between groups (p ¼ 0.015).
THRESHOLDS. The TBR thresholds based on the tolerance interval in healthy control subjects are listed in Table 3 . Based on the 90th percentile of this interval, the threshold for SUV max was 1.85 for the carotids and 2.38 for the aorta. For TBR max , this threshold was set at 1.84 for the carotids and 2.68 for the aorta. Figure 2 illustrates both the SUV max and TBR max values per group, with corresponding thresholds (red dashed lines). For SUV max , 39% to 43% of those at increased CVD risk versus 66% of the CVD patients exceeded these thresholds. For TBR max , these numbers were in general larger; 52% to 57% of those at increased CVD risk and 67% to 74% of CVD patients. In Online Table 4 , we also provide the thresholds using the 95th percentile values.
SAMPLE SIZES. Based on the TBR max values in the present study, Figure 3 depicts the sample sizes required for an estimated drug effect; ranging from 5% to 20%, as has been observed in previous drug trials (Online Table 1 Figure 2) . In addition, agreement for all 18 F-FDG metrics was also excellent in healthy control subjects (Online Tables 4 and 5 ).
DISCUSSION
In the present work, we tested 5 frequently applied approaches to quantify 18 F-FDG uptake in the arterial wall of healthy controls, patients at risk, and patients with known CVD. Whole artery SUV max was significantly different between groups, and 18 F-FDG venous blood background values were similar. As *Thresholds were determined using the 90th percentile value observed in the healthy control subjects.
Abbreviations as in Table 2 .
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Arterial PET/CT in Atherosclerosis As shown in Table 2 , differences in background 18 
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Scatterplots showing the gradual increase in SUV max and TBR max for the carotids (A and B) and aorta (C and D) in healthy control subjects, patients at CVD risk and patients with known CVD. The red dashed line represents the 90th percentile value in healthy control subjects.
CVD ¼ cardiovascular disease; TBR max ¼ maximum target to background ratio; other abbreviations as in Figure 1 .
Arterial PET/CT in Atherosclerosis studies with repeat imaging, the use of a ratio, such as TBR, limits the effect on signal quantification where variation between scans exists (e.g., weight change, 18 F-FDG dose change, 18 F-FDG circulation time change) (36) . For these reasons, we favor the use of TBR, as also endorsed in the recent European Association of Nuclear Medicine position paper on vascular PET imaging (36) .
With respect to the active segment approach, a substantial bias is induced by eliminating (a potentially large number of) included subjects and imaged slices (e.g., 48% of healthy subjects included in the carotid analysis). Consequently, the TBR active slice loses much of its power to differentiate between healthy and diseased subjects. Hence, this approach should be interpreted with caution, and might be better suited for changes within 1 individual (20, 26) .
INFLAMMATION IN DIFFERENT ARTERIAL BEDS.
The validation of 18 F-FDG as a marker of plaque inflammation originates from histology (5-7) and gene expression studies (37, 38) performed on human carotid plaque material. Over time, quantification of 18 F-FDG uptake in the aorta became adopted, supported by, among others, the histological work in rabbit models (39, 40) and the incremental value in cardiovascular risk stratification (11) . The present study was not designed to investigate the nature of 18 F-FDG vascular uptake, but nevertheless showed that SUVs and TBRs were consistently higher in the aorta compared with the carotids. This is relevant when applying an "index vessel approach" to drug trials because, in w80% of subjects, the index vessel will originate from the aorta (31). This might be suboptimal, as we also demonstrated that aortic TBR as endpoint requires a larger sample size to detect drug efficacy (37) . Taking into account that the published drug-induced TBR changes have been relatively small (ranging between 5% and 15%) (Online Table 1 ), the optimal choice of endpoint vessel is important. (34, 48) . Further, we document low interscan TBR changes (<3.5% over a 3-week period), which is in line with previous placebo-controlled Sample sizes required for studies using TBR max as the primary endpoint. These are dependent on the estimated drug effect (ranging between 5% and 20%) and target vessel for imaging (carotid artery or aorta). Abbreviation as in Figure 2 .
Arterial PET/CT in Atherosclerosis O C T O B E R 2 0 1 6 : 1 1 9 8 -2 0 7 intervention studies revealing small variations during a 3-to 6-month timeframe (19, 23 Arterial PET/CT in Atherosclerosis
